Each 12 weeks thereafter, as outlined by Response Evaluation Criteria in Solid Tumors

non-Japanese individuals, respectively, within the axitinib titration (604 vs. 409 days) plus the non-randomized arms (618 vs. 365 days); even so, a greater percentage of Japanese than nonJapanese sufferers, respectively, expected dose reductions (axitinib titration: 50 vs. 14 ; non-randomized: 50 vs. 39 ) (Table two).Age, median (variety), years 66 (42?1) 61 (28?7) 0.0231a Sex, n ( ) Male 30 (68) 113 (67) 1.0000b Epoxomicin Female 14 (32) 56 (33) Race, n ( ) White 0 162 (96) title= dar.12324 1). One Japanese and nine non-Japanese patients discontinued throughout the lead-in period. Following the lead-in period, 11 (25 ) Japanese individuals had been randomly assigned to axitinib (n = six) or placebo titration (n = 5) along with the remaining 32 Japanese patients continued axitinib therapy in the non-randomized arm, whereas 50 and 51 non-Japanese patients have been randomized to axitinib and placebo titration, respectively, plus the remaining 59 sufferers for the nonrandomized arm (Fig. two). In the major information cutoff date (12 October 2012), 48 of Japanese and 79 of non-Japanese patients discontinued therapy, mainly resulting from illness progression (Fig. two).